Rayleen M Lewis1, Lauri E Markowitz2. 1. Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, 1600 Clifton Road NE, Atlanta, GA 30329-4027, USA; Synergy America, Inc., 6340 Sugarloaf Parkway, Suite 200, Duluth, GA 30097, USA. Electronic address: Lry9@cdc.gov. 2. Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, 1600 Clifton Road NE, Atlanta, GA 30329-4027, USA.
Abstract
BACKGROUND: Human papillomavirus (HPV) vaccination has been routinely recommended at age 11-12 years in the United States for females since 2006 and males since 2011. Coverage can be estimated using self/parent-reported HPV vaccination collected in the National Health and Nutrition Examination Survey (NHANES) for a wider age range than other national surveys. We assessed vaccination coverage in 2015-2016, temporal trends by age, and the validity of self/parent-reported vaccination status. METHODS: Participants aged 9-59 years completed an interview collecting demographic and vaccination information. Weighted coverage was estimated for two-year NHANES cycles by age group for 2007-2008 to 2015-2016 for females (N = 14318) and 2011-2012 to 2015-2016 for males (N = 7847). Temporal trends in coverage were assessed from 2007-2008 to 2011-2012 for females and from 2011-2012 to 2015-2016 for both sexes. Sensitivity and specificity of self/parent-reported vaccination were assessed using provider-verified vaccination records from a pilot study in 14-29 year-olds. RESULTS: In 2015-2016, ≥1 dose coverage among females was highest in 14-19 (54.7%) and 20-24 (56.0%) year-olds and lower in successively older age groups. Among males, ≥1 dose coverage was highest in 14-19 year-olds (39.5%) and lower at older ages. Coverage was similar in 9-13 year-old females and males. Between 2007-2008 and 2011-2012, there were increases among females younger than 30 years. Between 2011-2012 and 2015-2016, there were increases among female age groups including 20-39 year-olds; male coverage increased among ages 9-13, 14-19, and 20-24 years. Self/parent-reported receipt of ≥1 dose had a sensitivity and specificity of 87.0% and 83.3%. Performance was lower for 3 doses. CONCLUSIONS: While overall HPV vaccination coverage remains low, it is higher in females than males, except in 9-13 year-olds. There have been increases in coverage among many age groups, but coverage has stalled in younger females. Adequate validity was demonstrated for self/parent-reported vaccination of ≥1 dose, but not 3 doses, in a pilot study.
BACKGROUND:Human papillomavirus (HPV) vaccination has been routinely recommended at age 11-12 years in the United States for females since 2006 and males since 2011. Coverage can be estimated using self/parent-reported HPV vaccination collected in the National Health and Nutrition Examination Survey (NHANES) for a wider age range than other national surveys. We assessed vaccination coverage in 2015-2016, temporal trends by age, and the validity of self/parent-reported vaccination status. METHODS:Participants aged 9-59 years completed an interview collecting demographic and vaccination information. Weighted coverage was estimated for two-year NHANES cycles by age group for 2007-2008 to 2015-2016 for females (N = 14318) and 2011-2012 to 2015-2016 for males (N = 7847). Temporal trends in coverage were assessed from 2007-2008 to 2011-2012 for females and from 2011-2012 to 2015-2016 for both sexes. Sensitivity and specificity of self/parent-reported vaccination were assessed using provider-verified vaccination records from a pilot study in 14-29 year-olds. RESULTS: In 2015-2016, ≥1 dose coverage among females was highest in 14-19 (54.7%) and 20-24 (56.0%) year-olds and lower in successively older age groups. Among males, ≥1 dose coverage was highest in 14-19 year-olds (39.5%) and lower at older ages. Coverage was similar in 9-13 year-old females and males. Between 2007-2008 and 2011-2012, there were increases among females younger than 30 years. Between 2011-2012 and 2015-2016, there were increases among female age groups including 20-39 year-olds; male coverage increased among ages 9-13, 14-19, and 20-24 years. Self/parent-reported receipt of ≥1 dose had a sensitivity and specificity of 87.0% and 83.3%. Performance was lower for 3 doses. CONCLUSIONS: While overall HPV vaccination coverage remains low, it is higher in females than males, except in 9-13 year-olds. There have been increases in coverage among many age groups, but coverage has stalled in younger females. Adequate validity was demonstrated for self/parent-reported vaccination of ≥1 dose, but not 3 doses, in a pilot study.
Authors: Lauri E Markowitz; Gui Liu; Susan Hariri; Martin Steinau; Eileen F Dunne; Elizabeth R Unger Journal: Pediatrics Date: 2016-02-22 Impact factor: 7.124
Authors: Eric Adjei Boakye; Betelihem B Tobo; Nosayaba Osazuwa-Peters; Kahee A Mohammed; Christian J Geneus; Mario Schootman Journal: Am J Prev Med Date: 2016-11-24 Impact factor: 5.043
Authors: Sara E Oliver; Elizabeth R Unger; Rayleen Lewis; Darius McDaniel; Julia W Gargano; Martin Steinau; Lauri E Markowitz Journal: J Infect Dis Date: 2017-09-01 Impact factor: 5.226
Authors: Susan Hariri; Michelle L Johnson; Nancy M Bennett; Heidi M Bauer; Ina U Park; Sean Schafer; Linda M Niccolai; Elizabeth R Unger; Lauri E Markowitz Journal: Cancer Date: 2015-06-22 Impact factor: 6.860
Authors: Sarah Reagan-Steiner; David Yankey; Jenny Jeyarajah; Laurie D Elam-Evans; C Robinette Curtis; Jessica MacNeil; Lauri E Markowitz; James A Singleton Journal: MMWR Morb Mortal Wkly Rep Date: 2016-08-26 Impact factor: 17.586
Authors: Julia W Gargano; Elizabeth R Unger; Gui Liu; Martin Steinau; Elissa Meites; Eileen Dunne; Lauri E Markowitz Journal: J Infect Dis Date: 2017-04-01 Impact factor: 5.226
Authors: Tanja Y Walker; Laurie D Elam-Evans; James A Singleton; David Yankey; Lauri E Markowitz; Benjamin Fredua; Charnetta L Williams; Sarah A Meyer; Shannon Stokley Journal: MMWR Morb Mortal Wkly Rep Date: 2017-08-25 Impact factor: 17.586
Authors: Vicki B Benard; Philip E Castle; Steven A Jenison; William C Hunt; Jane J Kim; Jack Cuzick; Ji-Hyun Lee; Ruofei Du; Michael Robertson; Scott Norville; Cosette M Wheeler Journal: JAMA Oncol Date: 2017-06-01 Impact factor: 31.777
Authors: Summer Sherburne Hawkins; Krisztina Horvath; Jessica Cohen; Lydia E Pace; Christopher F Baum Journal: Cancer Causes Control Date: 2021-04-17 Impact factor: 2.506
Authors: Jacqueline M Hirth; Yong-Fang Kuo; Jonathan M Starkey; Richard E Rupp; Tabassum H Laz; Mahbubur Rahman; Abbey B Berenson Journal: Vaccine Date: 2019-06-07 Impact factor: 3.641
Authors: Nicholas B Schmuhl; Katherine E Mooney; Xiao Zhang; Laura G Cooney; James H Conway; Noelle K LoConte Journal: Vaccine Date: 2020-04-03 Impact factor: 3.641
Authors: Paul L Reiter; Mira L Katz; José A Bauermeister; Abigail B Shoben; Electra D Paskett; Annie-Laurie McRee Journal: LGBT Health Date: 2018-07 Impact factor: 4.151
Authors: Terra Forward; Elissa Meites; John Lin; James P Hughes; Elizabeth R Unger; Lauri E Markowitz; Matthew Golden; Fred Swanson; Paul M Faestel; Rachel L Winer Journal: Sex Transm Dis Date: 2022-01-01 Impact factor: 2.830